Key results at the highest dose (24 mg): 22.5% placebo-adjusted mean weight loss at 48 weeks 96% achieved at least 5% weight loss 87% achieved at least 10% weight loss 48% achieved at least 20% weight loss 26% achieved at least 30% weight loss 54% reduced BMI below the obesity threshold (30 kg/m2) versus 13% placebo No weight loss plateau at 48 weeks Discontinuation due to adverse events: 5.9% (CT-388) vs 1.3% (placebo) Preclinical Data# CT-388 improved glycemic control in mice and monkeys, reduced body weight, suppressed appetite, and improved metabolic dysfunction-associated steatohepatitis (MASH) pathology in mice
Would you say that that checks out or is that sort of the wrong way to look at it
LC acts as an essential factor in the oxidation of fatty acids in the mitochondria and recent studies reported the great importance of its antioxidant and anti-inflammatory effects [,,]
[...] Rated 5 out of 5 Noah No irritation, just smooth, luminous skin
You could buy the same ingredients separately for less or put that money toward real GLP-1 care
Glucagon-like peptide 1 receptor agonists (GLP-1s) are a class of drugs that include semaglutide medications like Ozempic and Wegovy
